Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sachin Pai, MD
Corcept Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site Reference Id/investigator #109
Brussels, Belgium
- Site Reference Id/investigator #119
Edegem, Belgium
- Site Reference Id/investigator #108
Leuven, Belgium
- Site Reference Id/investigator #117
Toronto, Ontario, Canada
- Site Reference Id/investigator #096
Montreal, Quebec, Canada
- Site Reference Id/investigator #122
Milan, Italy
- Site Reference Id/investigator #112
Naples, Italy
- Site Reference Id/investigator #124
Roma, Italy
- Site Reference Id/investigator #115
Barcelona, Spain
- Site Reference Id/investigator #114
Madrid, Spain
- Site Reference Id/investigator #116
Madrid, Spain
- Site Reference Id/investigator #113
Valencia, Spain
- Site Reference Id/investigator #004
Birmingham, Alabama, United States
- Site Reference Id/investigator #038
Scottsdale, Arizona, United States
- Site Reference Id/investigator #032
Denver, Colorado, United States
- Site Reference Id/investigator #001
Chicago, Illinois, United States
- Site Reference Id/investigator #106
Boston, Massachusetts, United States
- Site Reference Id/investigator #128
Boston, Massachusetts, United States
- Site Reference Id/investigator #051
New York, New York, United States
- Site Reference Id/investigator #169
New York, New York, United States
- Site Reference Id/investigator #170
New York, New York, United States
- Site Reference Id/investigator #127
Pittsburgh, Pennsylvania, United States
- Site Reference Id/investigator #135
Charlottesville, Virginia, United States
- Site Reference Id/investigator #121
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 Apr 2019
- Primary completion
- 16 Mar 2021
- Completion
- 12 Jul 2023
- Last update posted
- 7 Oct 2025
- Registered enrollment
- 178
- Registry id
- NCT03776812
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.